avoralstat   Click here for help

GtoPdb Ligand ID: 11584

Synonyms: BCX-4161 | BCX4161
PDB Ligand
Compound class: Synthetic organic
Comment: Avoralstat (BCX-4161) is a small molecule, oral plasma kallikrein (a serine protease that generates bradykinin from kininogen) inhibitor [3]. Data pubished in 2021 indicate that avoralstat inhibits TMPRSS2 (a protease required for spike protein-mediated SARS-CoV-2 viral entry via ACE2) with comparable inhibitory activity to camostat [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 5
Rotatable bonds 12
Topological polar surface area 167.49
Molecular weight 513.2
XLogP 1.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(=N)N)c1ccc(nc1C(=O)O)C(=O)NCC1CC1
Isomeric SMILES COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(=N)N)c1ccc(nc1C(=O)O)C(=O)NCC1CC1
InChI InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37)
InChI Key TUWMKPVJGGWGNL-UHFFFAOYSA-N
References
1. Aygören-Pürsün E, Magerl M, Graff J, Martinez-Saguer I, Kreuz W, Longhurst H, Nasr I, Bas M, Straßen U, Fang L et al.. (2016)
Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
J Allergy Clin Immunol, 138 (3): 934-936.e5. [PMID:27302552]
2. Hu X, Shrimp JH, Guo H, Xu M, Chen CZ, Zhu W, Zakharov AV, Jain S, Shinn P, Simeonov A et al.. (2021)
Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19.
ACS Pharmacol Transl Sci, 4 (3): 1124-1135. [PMID:34136758]
3. Partridge JR, Choy RM, Silva-Garcia A, Yu C, Li Z, Sham H, Metcalf B. (2019)
Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition.
J Struct Biol, 206 (2): 170-182. [PMID:30876891]
4. Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein JA, Bouillet L, Busse P, Manning M, Magerl M et al.. (2018)
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Allergy, 73 (9): 1871-1880. [PMID:29688579]